MacroGenics' Lorigerlimab Shows 25% Response Rate In Clear Cell Gynecologic Cancer
MacroGenics (MGNX) reported Phase 2 trial results for lorigerlimab, showing a 25% response rate and 44% disease control rate in advanced clear cell gynecologic cancer. All responses were ongoing as of September 1, 2026. The company is testing a lower dose, with updated results expected in H1 2027. MGNX shares closed at $2.25 on Friday, down 38.02%, and were down 1.33% in pre-market trading.
How this was made
The 30-second read
Why it matters
The trial results provide the first public efficacy signal for lorigerlimab in this indication, setting a baseline for future development milestones.
Market read
First‑report trial data for a small‑cap biotech, modest efficacy, immediate price decline, medium‑term trading relevance.
What to watch
Potential for accelerated development path or partnership interest not reflected in the immediate price reaction.
Background
MacroGenics (MGNX) is a US‑listed biotech focused on antibody‑based cancer therapies. The interim data were presented ahead of the planned H1‑2027 update.
Ticker impact
MacroGenics reported interim Phase 2 data showing a 25% confirmed objective response rate in advanced clear cell gynecologic cancer.
likely further pressure as investors weigh the modest efficacy against high expectations.
Data is new and primary, but the 25% response is modest for a Phase 2 trial, and the stock has already dropped 38% historically and 1.33% pre‑market, suggesting continued downside sentiment.
Market effects
Oncology biotech sector may see modest re‑rating as investors assess early‑stage data across similar targets.
US biotech market could experience slight bearish pressure on small‑cap trial stocks.
Limited global impact; relevance confined to investors tracking early‑stage cancer therapeutics.
Counterpoint
The 44% disease control rate could be a catalyst for a rebound if later data shows deeper durability.
Key entities
- companyMacroGenics
US biotech developing antibody therapeutics.
- druglorigerlimab
Investigational antibody targeting clear cell gynecologic cancers.
